• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Assembly Biosciences Inc. (Amendment)

    2/10/22 4:06:59 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASMB alert in real time by email
    SC 13G/A 1 d289469dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 2)*

     

     

    Assembly Biosciences, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    045396108

    (CUSIP Number)

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the Appropriate Box to Designate the Rule Pursuant to Which this Schedule Is Filed:

     

    ☐

    Rule 13d-1(b)

     

    ☒

    Rule 13d-1(c)

     

    ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    Explanatory Note: Based on the number of outstanding shares of Common Stock disclosed by the Issuer on November 4, 2021, this Amendment No. 2 is being filed to report that the Reporting Person ceased to own more than 5% of the shares of Common Stock.

     

      1    

      Names of Reporting Person

      I.R.S. Identification No. of Above Person (Entities Only):

     

      Muneer A. Satter

      2  

      Check The Appropriate Box If a Member Of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      2,227,500

       6   

      Shared Voting Power

     

      0

       7   

      Sole Dispositive Power

     

      2,227,500

       8   

      Shared Dispositive Power

     

      0

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,227,500

    10  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      ☐

    11  

      Percent of Class Represented By Amount in Row (9)

     

      4.7% (a)

    12  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (a)

    All percentages calculated in this Schedule 13G/A are based upon 47,861,677 shares of common stock outstanding as of November 1, 2021, as disclosed in the Quarterly Report on Form 10-Q filed by Assembly Biosciences, Inc. with the Securities and Exchange Commission on November 4, 2021.


    Item 1(a).    Name of Issuer:
      

    Assembly Biosciences, Inc.

    Item 1(b).    Address of Issuer’s Principal Executive Offices:
      

    331 Oyster Point Blvd.

    South San Francisco, CA 94080

    Item 2(a).    Name of Person Filing:
      

    This Schedule 13G is being filed by Muneer A. Satter (the “Reporting Person”).

    Item 2(b).    Address of Principal Business Office or, if none. Residence:
      

    Muneer A. Satter

    c/o Satter Management Co., L.P.

    676 North Michigan Avenue, Suite 4000

    Chicago, IL 60611

    Item 2(c).    Citizenship:
      

    The Reporting Person is a citizen of the United States of America.

    Item 2(d).    Title of Class of Securities:
      

    Common Stock, par value $0.001 per share (the “Common Stock”).

    Items 2(e).    CUSIP Number:
      

    045396108


    Item 3.   

    If this statement is filed pursuant to 240.13d-l(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)  ☐  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)  ☐  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)  ☐  Insurance company as defined in section 3(a)(l 9) of the Act (15 U.S.C. 78c).

     

    (d)  ☐  Investment company registered under section 8 of the Investment Company Act of 1940 (15U.S.C. 80a-8).

     

    (e)  ☐  An investment adviser in accordance with §240.13d-l(b)(l )(ii)(E).

     

    (f)  ☐  An employee benefit plan or endowment fund in accordance with §240.13d-1 (b)( 1 )(ii)(F)

     

    (g)  ☐  A parent holding company or control person in accordance with § 240.13d-l (b)(l )(ii)(G).

     

    (h)  ☐  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)  ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)  ☐ Non-U.S. institution in accordance with Rule 13d-l(b)(l )(ii)(J).

     

    (k)  ☐  Group, in accordance with §240.13d-l(b)(l )(ii)(K).

    Item 4.    Ownership:
      

    (a)   Amount beneficially owned:

     

    The Reporting Person beneficially owns an aggregate of 2,227,500 shares of Common Stock. The shares of Common Stock beneficially owned by the Reporting Person include (a) 1,800,000 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares; (b) 215,147 shares of Common Stock that are held by Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares; and (c) 212,353 shares of Common Stock that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares.

     

    (b)   Percent of class:

     

    See Item 11 on the cover page hereto.

     

    (c)   Number of shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote:

     

    See Item 5 on the cover page hereto.

     

    (ii)  Shared power to vote or to direct the vote:

     

    0

     

    (iii)  Sole power to dispose or to direct the disposition of:

     

    See Item 7 on the cover page hereto.

     

    (iv) Shared power to dispose or to direct the disposition of:

     

    0


    Item 5.    Ownership of Five Percent or Less of a Class:
       If this statement is being filed to report the fact that as of the date hereof, the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒
    Item 6.    Ownership of More than Five Percent on Behalf of Another Person:
      

    Not Applicable.

    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding:
      

    Not Applicable.

    Item 8.    Identification and Classification of Members of the Group:
      

    Not Applicable

    Item 9.    Notice of Dissolution of Group:
      

    Not Applicable.

    Item 10.    Certification:
       By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 9, 2022
    By:  

    /s/ Muneer A. Satter

      Muneer A. Satter
    Get the next $ASMB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASMB

    DatePrice TargetRatingAnalyst
    9/24/2025$38.00Mkt Outperform
    Citizens JMP
    8/18/2025$50.00Buy
    H.C. Wainwright
    3/25/2025$31.00Buy
    Guggenheim
    9/20/2024$2.00 → $35.00Hold → Buy
    Jefferies
    9/13/2021$3.50Neutral
    HC Wainwright & Co.
    9/2/2021Outperform → Market Perform
    William Blair
    More analyst ratings

    $ASMB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

    – Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – Gilead Sciences, Inc. (NASDAQ:GILD) and Assembly Biosciences, Inc. (NASDAQ:ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio R&D collaboration, reinforcing the companies' commitment to building a novel antiviral pipeline and driving long-term

    12/22/25 8:00:00 AM ET
    $ASMB
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes

    – 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179, exceeding expectations for the study – – 76% reduction in HSV-2 shedding rate, 81% reduction in high viral load shedding rate and 88% reduction in virologically confirmed genital lesion rate observed in proof-of-concept test of monthly oral dose of ABI-5366 – – Company to hold conference call today at 6 p.m. ET – SOUTH SAN FRANCISCO, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting seri

    12/8/25 4:05:00 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates

    – Released positive Phase 1b interim results for long-acting helicase-primase inhibitor candidate ABI-5366 showing significant reductions in viral shedding rate and genital lesion rate in recurrent genital herpes – – Announced Phase 1a interim results for orally bioavailable HDV entry inhibitor candidate ABI-6250 supporting progression into Phase 2 evaluation – – Additional interim Phase 1b data readouts from HSV program anticipated to include monthly oral dosing for ABI-5366 and two cohorts of weekly oral dosing for ABI-1179, with data now expected by end of year – – Raised $175 million gross proceeds from equity financings – SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE)

    11/10/25 4:05:00 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gilead Sciences, Inc. bought 2,295,920 shares, increasing direct ownership by 104% to 4,505,391 units (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    10/3/25 4:30:21 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PFO and PAO Bjorkquist Jeanette M was granted 300 shares, increasing direct ownership by 6% to 5,097 units (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    6/17/25 4:05:04 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Houghton Michael

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    6/9/25 4:05:21 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citizens JMP initiated coverage on Assembly Biosciences with a new price target

    Citizens JMP initiated coverage of Assembly Biosciences with a rating of Mkt Outperform and set a new price target of $38.00

    9/24/25 7:55:39 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Assembly Biosciences with a new price target

    H.C. Wainwright resumed coverage of Assembly Biosciences with a rating of Buy and set a new price target of $50.00

    8/18/25 8:55:27 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Assembly Biosciences with a new price target

    Guggenheim initiated coverage of Assembly Biosciences with a rating of Buy and set a new price target of $31.00

    3/25/25 8:26:24 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gilead Sciences, Inc. bought 2,295,920 shares, increasing direct ownership by 104% to 4,505,391 units (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    10/3/25 4:30:21 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Houghton Michael bought $49,998 worth of shares (3,202 units at $15.61) (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    12/31/24 4:24:14 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gilead Sciences, Inc. bought $20,098,464 worth of shares (940,499 units at $21.37), increasing direct ownership by 74% to 2,209,471 units (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    12/23/24 8:26:39 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Assembly Biosciences Inc.

    SCHEDULE 13G/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    2/9/26 8:46:31 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assembly Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

    12/8/25 4:17:56 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Assembly Biosciences Inc.

    SCHEDULE 13G - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    12/8/25 11:43:35 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    Leadership Updates

    Live Leadership Updates

    View All

    Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

    -- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus (HBV), hepatitis C vi

    11/8/23 8:00:00 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes

    −ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced the selection of development candidate ABI-5366 (5366) to progress to IND-enabling studies for its long-acting herpes simplex virus type 2 (HSV-2) helicase inhibitor program. 5366 is the first development candidate from Assembly Bio's discovery pipeline nominated for adv

    2/15/23 8:00:00 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

    Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB. Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D. "I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board," said Dr. Walter Strapps, co-founder and CEO of Carver. "Along with Dr. Myhrvold, these scientific leaders will help us shape our pipeline and advance our programs into the clinic." Uri Lopatin, M.D. Dr. Lopatin is a serial biotech entrepreneur who founde

    1/17/23 7:00:00 AM ET
    $ASMB
    $PRDS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    $ASMB
    Financials

    Live finance-specific insights

    View All

    Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes

    – 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179, exceeding expectations for the study – – 76% reduction in HSV-2 shedding rate, 81% reduction in high viral load shedding rate and 88% reduction in virologically confirmed genital lesion rate observed in proof-of-concept test of monthly oral dose of ABI-5366 – – Company to hold conference call today at 6 p.m. ET – SOUTH SAN FRANCISCO, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting seri

    12/8/25 4:05:00 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Assembly Biosciences Inc.

    SC 13G - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    11/14/24 3:22:29 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Assembly Biosciences Inc.

    SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    6/24/24 4:28:09 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Assembly Biosciences Inc.

    SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    6/20/24 8:35:37 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care